Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

Immune-Related Conditions

What research shows for peptides marketed for immunity, from thymosin alpha-1 trials in sepsis, COVID-19 and hepatitis B to KPV, plus approved peptide medicines for specific immune conditions.

Content last updated . This page has not been medically reviewed.

Back to Peptides & Modern Research
Quick answer
"Immune-related conditions" covers very different problems: severe infection, long-term viral infection, autoimmune disease, allergy-type swelling. No peptide has proven general immune benefit for healthy people. In the sources checked for this page, the human evidence for the most-discussed immune peptide, thymosin alpha-1, is mixed. The one promoted tripeptide checked here, KPV, has animal data only. A few approved peptide medicines exist, but each treats one named condition.

Evidence labels used here. Approved medicine: a regulator approved it for a named use. Promising but limited: some human data, small or inconsistent. Mixed: good studies disagree. Preclinical: cells or animals only. Proper evidence not found: we looked and found nothing usable. A change in an immune-cell marker is a biomarker; survival or fewer infections is a clinical outcome. For everyday immune health, see Immune Health and Immune Research and Evidence.

Thymosin alpha-1

Thymosin alpha-1 (Ta1) is a peptide that occurs naturally in the thymus. [1] As a drug, Ta1 is described as a synthetic polypeptide. [2] Background on the thymic family is on Thymic Peptides and Immune Signaling. Below, each pairing names the condition, because results in one condition do not carry over to another.
Condition and studyDesign and peopleMain resultFunding and limits
Severe sepsis, ETASS (2013)Single-blind randomized trial in six Chinese teaching hospitals; 361 intensive care patients, Ta1 added to usual care versus usual care alone [3]Death within 28 days 26.0% with Ta1 versus 35.0% without, a borderline result (p = 0.062); a blood immune marker (mHLA-DR) improved more on Ta1 [3]Single-blind, so staff knew who got Ta1. No serious drug-related event recorded. [3]
Sepsis, TESTS (2025)Double-blind, placebo-controlled phase 3 trial at 22 Chinese centres; 1,106 adults enrolled, 7 days of injections [4]Death within 28 days 23.4% with Ta1 versus 24.1% with placebo; no clear benefit; no secondary or safety outcome differed [4]Support included SciClone Pharmaceuticals. [4] Subgroup differences by age and diabetes were flagged as potential, not proven. [4]
Sepsis, pooled analysis (2025)11 randomized trials, 967 treated and 960 control patients [5]Overall lower 28-day death, but the high-quality and multicentre subgroups showed no clear benefit [5]The authors said the total sample was too small to be sure. [5]
Chronic hepatitis B, Cochrane review (2026)10 randomized trials, 1,349 people, follow-up six months to five years [6]Authors rated the certainty of evidence very low for nearly all outcomes (low for serious adverse events) and were not sure of benefit [6]Four trials had industry funding. [6]
Hospitalized COVID-19, two pooled analyses (2023)One pooled 9 studies; the other pooled 8 [7][8]One found no significant effect on death and did not support use; the other suggested lower death but said randomized trials were still needed [7][8]Both pooled results varied widely between studies (I² of 90% and 84%). The two reviews disagree. [7][8]

Plain reading: mixed, trending toward "not shown". The largest, best-controlled sepsis trial found no mortality difference. The sepsis trials also differ in era (ETASS ran 2008 to 2010, TESTS 2016 to 2020), size and blinding, [3][4] which is one reason their answers differ.

Regulatory note (United States). Thymosin alpha-1 appears on the FDA page titled "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 04/22/2026, read 2026-10-22), in the section "nominated but withdrawn". That section is described as substances previously in category 2 that were withdrawn by the nominators. [9] FDA's text says compounded Ta1 may pose significant risk for immunogenicity for certain routes. [9] This page did not verify approval status in any other country. See Approved, Investigational and Unapproved Peptides for what these categories mean.

KPV

KPV is a three-amino-acid fragment of a natural hormone, alpha-MSH. In one study, mice with experimentally induced colitis recovered faster with KPV, and the authors called it an interesting option for inflammatory bowel disease. [10] That is preclinical. On the same FDA page, FDA says it has not identified any human exposure data on drug products containing KPV by any route. [9] Evidence label: insufficient evidence in people.

Frequently asked questions

Do peptides strengthen the immune system?

Proper evidence not found for healthy people. The best-studied immune peptide, thymosin alpha-1, has mixed results in specific illnesses. [4][6]

Did thymosin alpha-1 work for sepsis?

An earlier single-blind trial hinted at benefit. A later double-blind trial of 1,106 adults found no clear difference in 28-day death. [3][4]

Is thymosin alpha-1 proven for hepatitis B or COVID-19?

No. A 2026 Cochrane review rated the hepatitis B evidence very low certainty, and COVID-19 reviews disagree. [6][7][8]

Has KPV been tested in people?

FDA said on its page that it had not identified human exposure data on KPV drug products. The research found is in mice. [9][10]

Are any immune-related peptide medicines approved?

Yes, for specific conditions, such as icatibant for hereditary angioedema attacks and glatiramer for relapsing multiple sclerosis. [11][12]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Approved peptide medicines for immune-related conditions
These show that approved options exist for a few named conditions only.
  • Icatibant (Firazyr) is a synthetic peptide, a bradykinin B2 receptor blocker. [11] The US label covers treatment of acute attacks of hereditary angioedema in adults. [11] It does not strengthen immunity.
  • Glatiramer acetate (Copaxone) is made of synthetic polypeptides built from four amino acids. [12] The US label covers relapsing forms of multiple sclerosis in adults. [12]

Neither label says anything about general immune support. See Immunodeficiency and Autoimmune Conditions.

Safety and next steps
Severe infection, immune deficiency and autoimmune disease need medical care. Please do not replace treatment with a promoted peptide. For checking claims, see How to Evaluate Peptide Claims and Clinic Marketing.
References
  1. Thymosin alpha 1: A comprehensive review of the literature. World J Virol 2020. PubMed abstract read 2026-10-22.
  2. Thymosin alpha-1. Am J Health Syst Pharm 2001. PubMed abstract read 2026-10-22.
  3. Wu J et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013. PubMed abstract read 2026-10-22.
  4. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ 2025. PubMed abstract read 2026-10-22.
  5. Efficacy of thymosin alpha1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol 2025. PubMed abstract read 2026-10-22.
  6. Thymosin-alpha1 for people with chronic hepatitis B. Cochrane Database Syst Rev 2026. PubMed abstract read 2026-10-22.
  7. Thymosin alpha1 use in adult COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Int Immunopharmacol 2023. PubMed abstract read 2026-10-22.
  8. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology 2023. PubMed abstract read 2026-10-22.
  9. FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page content current as of 04/22/2026). Read 2026-10-22.
  10. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. PubMed abstract read 2026-10-22.
  11. FIRAZYR (icatibant) injection, prescribing information (DailyMed, Takeda; version published 2025-07-17). Read 2026-10-22.
  12. COPAXONE (glatiramer acetate) injection, prescribing information (DailyMed, Teva Neuroscience; label read 2026-10-22). Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.